Introduction
============

Breast cancer is the second leading cause of cancer-associated mortality among women worldwide ([@b1-ol-0-0-10722]). According to one published report, there were \>240,000 new cases of breast cancer reported in the United States in 2017, of which \>40,000 were expected to succumb to the disease ([@b2-ol-0-0-10722]). Distant metastasis and chemoresistance are leading causes of patient mortality and treatment failure ([@b3-ol-0-0-10722]). Despite advances in the screening, diagnosis and treatment options for breast cancer, the incidence and mortality of the disease are still increasing ([@b4-ol-0-0-10722]). Tumor recurrence and metastatic relapse remain the major contributing factors to the high mortality rates ([@b5-ol-0-0-10722]). Therefore, there is still an urgent need to investigate novel targets and/or biomarkers that can be used to predict or treat patients with breast cancer.

Melanoma-associated antigen (MAGE) family members are cancer/testis antigens that are expressed in germline cells, trophoblasts and various types of human cancer, including melanoma, lung cancer, breast cancer, oral squamous cell carcinoma, esophageal carcinoma, urothelial malignancies and hematopoietic malignancies ([@b6-ol-0-0-10722]--[@b11-ol-0-0-10722]). At present, \>60 proteins in this family have been identified and subdivided into two categories on the basis of the location and expression patterns of the protein. The type I MAGE genes are restricted to clusters on the X-chromosome, and include MAGE-A, -B and -C. Their aberrant expression levels occur in numerous types of cancer and they serve as tumor-specific antigens ([@b11-ol-0-0-10722],[@b12-ol-0-0-10722]). Unlike the type I genes, type II MAGE genes are not limited to chromosome clustering and include MAGE-D, -E, -F, -G, -H, -I, -J, -K, -L and necdin subfamilies ([@b11-ol-0-0-10722],[@b12-ol-0-0-10722]). They serve an important role in cell cycle withdrawal, neuronal differentiation and apoptosis ([@b13-ol-0-0-10722]).

It has been reported that MAGEA1 can inhibit the proliferation and migration of MCF-7 and MDA-MB-231 breast cancer cell lines ([@b14-ol-0-0-10722]). In addition, MAGEA1-A3 and A12 have been investigated in the early detection of breast cancer ([@b15-ol-0-0-10722]). Ayyoub *et al* ([@b16-ol-0-0-10722]) reported that MAGEA3 and MAGEA6 expression in primary breast cancer is associated with hormone receptor-negative status, high histological grade and poor survival. Cabezón *et al* ([@b17-ol-0-0-10722]) indicated that MAGEA3 and MAGEA4 may be associated with risk and the clinicopathological parameters of breast cancer ([@b17-ol-0-0-10722],[@b18-ol-0-0-10722]). In breast cancer, MAGEA9-A11 have been identified as being associated with poor prognosis ([@b19-ol-0-0-10722]--[@b23-ol-0-0-10722]). Sypniewska *et al* ([@b24-ol-0-0-10722],[@b25-ol-0-0-10722]) demonstrated that MAGEB1-B3 DNA vaccines are useful for breast cancer therapy in a mouse breast tumor model. Hou *et al* ([@b26-ol-0-0-10722]) reported that MAGEC1 and MAGEC2 may be potential targets for tumor immunotherapy, and demonstrated that MAGEC1 and MAGEC2 expression is associated with advanced stages of breast cancer and poor patient outcome. Du *et al* ([@b27-ol-0-0-10722]) demonstrated that MAGED1 inhibits the proliferation, migration and invasion of human breast cancer cells. However, the prognostic roles of each individual MAGE, particularly at the mRNA level in breast cancer, remain unknown.

The Kaplan-Meier plotter (KM-Plotter) database (<http://kmplot.com/analysis/>) is generated gene expression data and survival information of 1,809 patients downloading from Gene Expression Omnibus (GEO) ([@b28-ol-0-0-10722]). This database has been widely used to analyze the clinical impact of individual genes on relapse-free survival (RFS), distant metastasis-free survival (DMFS), overall survival (OS) and post-progression survival (PPS) for different types of cancer. In the present study, the prognostic role of the mRNA expression of each individual member of the MAGE family in breast cancer was assessed using the Kaplan-Meier plotter database.

Materials and methods
=====================

### Data collection

The KM-Plotter database contains data regarding the survival of 3,955 patients with breast cancer (RFS data) ([@b28-ol-0-0-10722]). The association between the mRNA expression levels of individual MAGE family member genes and RFS was analyzed using an online KM-Plotter database using the gene expression data and the survival information of patients with breast cancer downloaded from the GEO (<https://www.ncbi.nlm.nih.gov/pubmed/20020197>) ([@b28-ol-0-0-10722]). Cohorts of patients were split by median expression values through auto select best cut-off. A collection of clinical data, including estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 (HER2) status, lymph node status, tumor pathological grade ([@b29-ol-0-0-10722]), intrinsic subtype and TP53 status were collected.

### Different subtypes of breast cancer analysis by KM-Plotter

Briefly, 29 individual members of the MAGE family were entered into the database ([kmplot.com/analysis/index.php?p=service&start=1](kmplot.com/analysis/index.php?p=service&start=1)) to obtain Kaplan-Meier survival plots. Of the 29 individual members of the MAGE family, 14 were selected to focus on: MAGEA5, -A8, -B4, -B6, -B18, -C3, -D2, -D3, -D4, -E1, -E2, -F1, -H1 and -L2, which, to the best of our knowledge, have not been reported in the literature by searching PubMed (<https://www.ncbi.nlm.nih.gov/pubmed/>), Elsevier ScienceDirect (<http://www.sciencedirect.com/>) and Google Scholar (<https://scholar.google.com/>). Subsequently, they were used to analyze the different subtypes of breast cancer by KM-Plotter.

### Clinicopathological features of breast cancer by KM-Plotter

In addition, in order to further examine the clinicopathological survival condition 14 genes were studied. The clinicopathological features of breast cancer through the KM-Plotter, including the lymph node status, tumor grade, TP53 status and Pietenpol subtype ([@b30-ol-0-0-10722]) were examined.

### Statistical analysis

The Kaplan-Meier survival plots with number at risk, hazard ratio (HR), 95% confidence intervals (CI) and log-rank P-values were obtained using the Kaplan-Meier plotter website. According to American Psychological Association (APA) formatting for P-values, P\<0.05 was used indicate a statistically significant difference.

Results
=======

### Prognostic values of MAGE members in all patients with breast cancer

The prognostic values of the mRNA expression levels of 29 MAGE family members in patients with breast cancer were obtained from the Kaplan-Meier plotter website. Among these 29 MAGE members, 28 were significantly associated with the prognosis of all types of breast cancer ([Fig. 1A](#f1-ol-0-0-10722){ref-type="fig"}). High mRNA expression levels of MAGEA1 (HR, 0.81; 95% CI, 0.71--0.91; P=0.0005), MAGEA4 (HR, 0.84; 95% CI, 0.75--0.93; P=0.0012), MAGEA5 (HR, 0.79; 95% CI, 0.71--0.88; P=2.5×10^−5^), MAGEA6 (HR, 0.87; 95% CI, 0.77--0.98; P=0.0200), MAGEA8 (HR, 0.71; 95% CI, 0.63--0.79; P=4.0×10^−10^), MAGEA9 (HR, 0.82; 95% CI, 0.72--0.93; P=0.0016), MAGEA10 (HR, 0.63; 95% CI, 0.56--0.71; P=3.7×10^−15^), MAGEA11 (HR, 0.80; 95% CI, 0.71--0.90; P=0.0003), MAGEA12 (HR, 0.79; 95% CI, 0.70--0.89; P=8.7×10^−5^) ([Fig. 1B-1/4/5/6/8/9/10/11](#f1-ol-0-0-10722){ref-type="fig"}); MAGEB1 (HR, 0.82; 95% CI, 0.74--0.92; P=0.0005), MAGEB2 (HR, 0.68; 95% CI, 0.61--0.76; P=6.8×10^−12^), MAGEB3 (HR, 0.83; 95% CI, 0.74--0.93; P=0.0017), MAGEB4 (HR, 0.84; 95% CI, 0.73--0.95; P=0.0058), MAGEB6 (HR, 0.78; 95% CI, 0.65--0.92; P=0.0031), MAGEC1 (HR, 0.72; 95% CI, 0.64--0.82; P=2.2×10^−7^), MAGEC2 (HR, 0.67; 95% CI, 0.60--0.75; P=6.7×10^−13^), MAGEC3 (HR, 0.76; 95% CI, 0.68--0.86; P=7.5×10^−6^), MAGED2 (HR, 0.78; 95% CI, 0.69--0.87; P=3.1×10^−5^), MAGED3 (HR, 0.82; 95% CI, 0.74--0.92; P=0.0009), MAGEE1 (HR, 0.73; 95% CI, 0.62--0.86; P=8.7×10^−5^), MAGEF1 (HR, 0.76; 95% CI, 0.67--0.85; P=4.2×10^−6^) and MAGEL2 (HR, 0.77; 95% CI, 0.68--0.87; P=4.3×10^−5^) ([Fig. 1C-1/2/3/4/5/7/8/9/11/12/14/16/18](#f1-ol-0-0-10722){ref-type="fig"}) were observed to be significantly associated with better prognosis. High mRNA expression levels of MAGED1 (HR, 1.49; 95% CI, 1.33--1.68; P=8.1×10^−12^), MAGED4 (HR, 1.26; 95% CI, 1.13--1.42; P=6.6×10^−5^) and MAGEH1 (HR, 1.29; 95% CI, 1.15--1.45; P=1.7×10^−5^) ([Fig. 1C-10/13/17](#f1-ol-0-0-10722){ref-type="fig"}) were significantly associated with worse RFS, whereas the expression levels of MAGEA2 (HR, 1.11; 95% CI, 0.99--1.23; P=0.0700) ([Fig. 1B-2](#f1-ol-0-0-10722){ref-type="fig"}) were not associated with RFS. High mRNA expression levels of MAGEA3 (HR, 0.87; 95% CI, 0.77--0.98; P=0.0270; [Fig. 1B-3](#f1-ol-0-0-10722){ref-type="fig"}) and MAGEE2 (HR, 0.81; 95% CI, 0.67--0.98; P=0.0290; [Fig. 1C-15](#f1-ol-0-0-10722){ref-type="fig"}) were significantly associated with improved prognosis, and low mRNA expression of MAGEB18 (HR, 1.17; 95% CI, 1.00--1.36; P=0.0490; [Fig. 1C-6](#f1-ol-0-0-10722){ref-type="fig"}) was significantly associated with better prognosis.

### Prognostic value of 14 MAGE members in different subtypes of breast cancer

The prognostic values of 14 MAGE members within the different intrinsic subtypes of breast cancer were determined, including all basal-like, luminal A, luminal B and HER2^+^. As presented in [Fig. 2](#f2-ol-0-0-10722){ref-type="fig"}, high mRNA expression levels of MAGEA8 (HR, 0.59; 95% CI, 0.45--0.77; P=7.9×10^−5^; [Fig. 2B](#f2-ol-0-0-10722){ref-type="fig"}), MAGEB4 (HR, 0.61; 95% CI, 0.46--0.82; P=0.0009; [Fig. 2C](#f2-ol-0-0-10722){ref-type="fig"}) and MAGEB6 (HR, 0.61; 95% CI, 0.43--0.85; P=0.0035; [Fig. 2D](#f2-ol-0-0-10722){ref-type="fig"}) were significantly associated with improved RFS in patients with the basal-like breast cancer subtype. High mRNA expression levels of MAGEA5 (HR, 0.75; 95% CI, 0.58--0.98; P=0.0320; [Fig. 2A](#f2-ol-0-0-10722){ref-type="fig"}), MAGEC3 (HR, 0.70; 95% CI, 0.52--0.94; P=0.0180; [Fig. 2E](#f2-ol-0-0-10722){ref-type="fig"}) MAGEE2 (HR, 0.64; 95% CI, 0.43--0.94; P=0.0230; [Fig. 2G](#f2-ol-0-0-10722){ref-type="fig"}) and MAGEF1 (HR, 0.73; 95% CI, 0.56--0.95; P=0.0170; [Fig. 2H](#f2-ol-0-0-10722){ref-type="fig"}) were significantly associated with improved RFS in patients with basal-like breast cancer subtype. However, high mRNA expression levels of MAGEH1 (HR, 1.51; 95% CI, 1.17--1.96; P=0.0016; [Fig. 2I](#f2-ol-0-0-10722){ref-type="fig"}) were significantly associated with worse RFS in patients with the basal-like breast cancer subtype and high mRNA expression levels of MAGED2 (HR, 1.34; 95% CI, 1.02--1.74; P=0.0330; [Fig. 2F](#f2-ol-0-0-10722){ref-type="fig"}) was significantly associated with improved RFS in patients with basal-like breast cancer subtype. The survival curves for the remaining members of the MAGE family in patients with basal-like breast cancer subtype were investigated, but they were not significantly associated with prognosis ([Fig. S1](#SD1-ol-0-0-10722){ref-type="supplementary-material"}).

In patients with luminal A breast cancer, high mRNA expression levels of MAGEA5 (HR, 0.71; 95% CI, 0.60--0.84; P=8.9×10^−5^; [Fig. 3A](#f3-ol-0-0-10722){ref-type="fig"}), MAGEA8 (HR, 0.69; 95% CI, 0.58--0.83; P=6.6×10^−5^; [Fig. 3B](#f3-ol-0-0-10722){ref-type="fig"}), MAGEC3 (HR, 0.71; 95% CI, 0.59--0.85, P=0.0003; [Fig. 3D](#f3-ol-0-0-10722){ref-type="fig"}); MAGED3 (HR, 0.71; 95% CI, 0.58--0.88; P=0.0016; [Fig. 3E](#f3-ol-0-0-10722){ref-type="fig"}), MAGEF1 (HR, 0.74; 95% CI, 0.61--0.88; P=0.0009; [Fig. 3G](#f3-ol-0-0-10722){ref-type="fig"}) and MAGEL2 (HR, 0.73; 95% CI, 0.60--0.88; P=0.0013; [Fig. 3I](#f3-ol-0-0-10722){ref-type="fig"}) were significantly associated with improved RFS. In contrast, high mRNA expression levels of MAGEH1 (HR, 1.20; 95% CI, 1.01--1.43; P=0.0350; [Fig. 3H](#f3-ol-0-0-10722){ref-type="fig"}) were significantly associated with worse RFS. High expression levels of MAGEB4 (HR, 0.84; 95% CI, 0.70--1.00; P=0.0470; [Fig. 3C](#f3-ol-0-0-10722){ref-type="fig"}) and MAGEE1 (HR, 0.74; 95% CI, 0.57--0.96; P=0.0250; [Fig. 3F](#f3-ol-0-0-10722){ref-type="fig"}) were significantly associated with improved RFS. The remaining MAGE family members were not significantly associated with the prognosis of luminal A breast cancer ([Fig. S2](#SD1-ol-0-0-10722){ref-type="supplementary-material"}).

In luminal B breast cancer, high mRNA expression levels of MAGEA5 (HR, 0.70; 95% CI, 0.58--0.85; P=0.0002; [Fig. 4A](#f4-ol-0-0-10722){ref-type="fig"}), MAGEA8 (HR, 0.68; 95% CI, 0.56--0.83; P=9.6×10^−5^; [Fig. 4B](#f4-ol-0-0-10722){ref-type="fig"}), MAGEB4 (HR, 0.72; 95% CI, 0.59--0.89; P=0.0020; [Fig. 4C](#f4-ol-0-0-10722){ref-type="fig"}), MAGEC3 (HR, 0.73; 95% CI, 0.60--0.88; P=0.0011; [Fig. 4E](#f4-ol-0-0-10722){ref-type="fig"}), MAGED3 (HR, 0.78; 95% CI, 0.64--0.94; P=0.0110; [Fig. 4F](#f4-ol-0-0-10722){ref-type="fig"}), MAGEE1 (HR, 0.68; 95% CI, 0.49--0.93; P=0.0016; [Fig. 4G](#f4-ol-0-0-10722){ref-type="fig"}) was significantly associated with improved RFS. High mRNA expression levels of MAGEL2 (HR, 0.80; 95% CI, 0.66--0.97; P=0.0210; [Fig. 4I](#f4-ol-0-0-10722){ref-type="fig"}) was significantly associated with improved RFS. However, high mRNA expression levels of MAGEH1 (HR, 1.55; 95% CI, 1.26--1.90; P=2.4×10^−5^; [Fig. 4H](#f4-ol-0-0-10722){ref-type="fig"}) was significantly associated with worse RFS and high mRNA expression levels of MAGEB18 (HR, 1.44; 95% CI, 1.06--1.97; P=0.0200; [Fig. 4D](#f4-ol-0-0-10722){ref-type="fig"}) was significantly associated with worse RFS. The remaining MAGE members were not significantly associated with the prognosis of luminal B breast cancer ([Fig. S3](#SD1-ol-0-0-10722){ref-type="supplementary-material"}).

In HER2^+^ breast cancer, high mRNA expression levels of MAGEA8 (HR, 0.67; 95% CI, 0.46--0.99; P=0.0410; [Fig. 5A](#f5-ol-0-0-10722){ref-type="fig"}) and MAGEC3 (HR, 0.62; 95% CI, 0.42--0.90; P=0.0120; [Fig. 5B](#f5-ol-0-0-10722){ref-type="fig"}) were significantly associated with improved RFS. However, high mRNA expression levels of MAGED2 (HR, 1.82; 95% CI, 1.24--2.68; P=0.0020; [Fig. 5C](#f5-ol-0-0-10722){ref-type="fig"}) and MAGEH1 (HR, 1.79; 95% CI, 1.21--2.64; P=0.0032; [Fig. 5D](#f5-ol-0-0-10722){ref-type="fig"}) were significantly associated with worse RFS. The remaining MAGE family members were not significantly associated with the RFS of HER2^+^ breast cancer ([Fig. S4](#SD1-ol-0-0-10722){ref-type="supplementary-material"}).

### Prognostic values of 14 MAGE members in breast cancer according to clinicopathological features

The present study also investigated the association between the MAGE family members and patients\' clinicopathological features. As presented in [Table I](#tI-ol-0-0-10722){ref-type="table"}, high mRNA expression levels of MAGEF1 (HR, 0.75; 95% CI, 0.61--0.93; P=0.0094) were significantly associated with improved RFS in lymph node-positive breast cancer. In contrast, high mRNA expression levels of MAGEF1 (HR, 1.26; 95% CI, 1.07--1.50; P=0.0063) were significantly associated with worse RFS in lymph node-negative breast cancer. High mRNA expression levels of MAGED2 were significantly associated with improved RFS in lymph node-positive breast cancer (HR, 0.79; 95% CI, 0.65--0.96; P=0.0200) and lymph node-negative breast cancer (HR, 0.82; 95% CI, 0.68--0.99; P=0.0400) breast cancer. MAGED4 expression levels were significantly associated with worse prognosis in lymph node-positive breast cancer (HR, 1.24; 95% CI, 1.02--1.51; P=0.0290) and significantly associated with worse prognosis in lymph node-negative breast cancer (HR, 1.27; 95% CI, 1.07--1.51; P=0.0062). High mRNA expression levels of MAGED3 (HR, 0.81; 95% CI, 0.67--0.99; P=0.0390) were significantly associated with improved RFS in lymph node-positive breast cancer. High mRNA expression levels of MAGEA5 (HR, 1.24; 95% CI, 1.00--1.53; P=0.0447), MAGED4 (HR, 1.24; 95% CI, 1.02--1.51; P=0.0290) and MAGEH1 (HR, 1.30; 95% CI, 1.04--1.62; P=0.0185) were significantly associated with worse RFS in lymph node-positive breast cancer. However, high mRNA expression levels of MAGEB6 (HR, 0.55; 95% CI, 0.33--0.91; P=0.0188), MAGEE2 (HR, 0.57; 95% CI, 0.33--0.98; P=0.0376) and MAGEL2 (HR, 0.83; 95% CI, 0.69--1.00; P=0.0464) were significantly associated with improved RFS in lymph node-negative breast cancer. The remaining MAGE family members were not significantly associated with the RFS of lymph node positive and negative breast cancer.

As presented in [Table II](#tII-ol-0-0-10722){ref-type="table"}, high mRNA expression levels of MAGEB6 (HR, 0.29; 95% CI, 0.10--0.83; P=0.0136), MAGEE1 (HR, 0.35; 95% CI, 0.12--1.02; P=0.0435) and MAGEH1 (HR, 0.52; 95% CI, 0.30--0.88; P=0.0140) in grade I breast cancer; MAGEA8 (HR, 0.74; 95% CI, 0.57--0.96; P=0.0248) and MAGEC3 (HR, 0.74; 95% CI, 0.57--0.96; P=0.0210) in grade II breast cancer; and MAGEA8 (HR, 0.78; 95% CI, 0.61--0.99; P=0.0373) in grade III breast cancer were significantly associated with improved RFS. High expression levels of MAGEF1 (HR, 0.70; 95% CI, 0.54--0.90; P=0.0057) and MAGEH1 (HR, 0.63; 95% CI, 0.47--0.85, P=0.0020) in grade II breast cancer; and MAGEB4 (HR, 0.72; 95% CI, 0.58--0.90; P=0.0041) and MAGEB6 (HR, 0.62; 95% CI, 0.46--0.85; P=0.0029) in grade III breast cancer were significantly associated with improved RFS.

High mRNA expression levels of MAGEB4 (HR, 1.91; 95% CI, 1.06--3.43; P=0.0288) and MAGEB18 (HR, 3.46; 95% CI, 1.20--9.98; P=0.0142) in grade I breast cancer were significantly associated with worse RFS; high mRNA expression levels of MAGED4 (HR, 1.52; 95% CI, 1.18--1.95; P=0.0009) in grade II breast cancer; and MAGED2 (HR, 1.39; 95% CI, 1.11--1.73; P=0.0042), MAGED3 (HR, 1.35; 95% CI, 1.07--1.69; P=0.0101), MAGEE1 (HR, 1.53; 95% CI, 1.12--2.08; P=0.0075) in grade III breast cancer were significantly associated with worse RFS; high mRNA expression levels of MAGEL2 (HR, 1.25; 95% CI, 1.01--1.56; P=0.0420) in grade III were significantly associated with worse RFS. The remaining MAGE family members were not associated with the RFS of different grade breast cancer.

As shown in [Table III](#tIII-ol-0-0-10722){ref-type="table"}, high mRNA expression levels of MAGEB4 (HR, 0.53; 95% CI, 0.31--0.88; P=0.0136) and MAGED3 (HR, 0.59; 95% CI, 0.37--0.95; P=0.0280) were significantly associated with improved RFS in patients with TP53-mutated breast cancer, whereas high mRNA expression levels of MAGEL2 (HR, 0.58; 95% CI, 0.34--0.99; P=0.0430) were significantly associated with improved RFS in TP53 wild-type breast cancer. In contrast, high mRNA expression levels of MAGED2 (HR, 2.10; 95% CI, 1.28--3.46; P=0.0028) were significantly associated with worse RFS in TP53-mutated breast cancer. High mRNA expression levels of MAGEB18 (HR, 3.51; 95% CI, 1.50--8.22; P=0.0021) and MAGED4 (HR, 1.82; 95% CI, 1.18--2.83; P=0.0065) were significantly associated with worse RFS in TP53 wild-type breast cancer; and high mRNA expression levels of MAGEE2 (HR, 2.35; 95% CI, 1.01--5.48; P=0.0414), MAGEB6 (HR, 5.08; 95% CI, 1.18--21.89; P=0.0157) were significantly associated with worse RFS in TP53 wild-type breast cancer. Notably, high mRNA expression levels of MAGEF1 were significantly associated with worse RFS in TP53-mutated (HR, 1.68; 95% CI, 1.04--2.71; P=0.0318) and TP53 wild-type (HR, 1.65; 95% CI, 1.06--2.55; P=0.0240) breast cancer. The remaining MAGE family members were not significantly associated with RFS of TP53 mutated and wild-type breast cancer.

As presented in [Table IV](#tIV-ol-0-0-10722){ref-type="table"}, high mRNA expression levels of MAGEA8 in the basal-like 1 subtype (HR, 0.50; 95% CI, 0.31--0.83; P=0.0059) and luminal androgen receptor subtype (HR, 0.52; 95% CI, 0.31--0.85; P=0.0076); and MAGEB18 in mesenchymal stem-like breast cancer subtype (HR, 0.19; 95% CI, 0.05--0.66; P=0.0039) were significantly associated with improved RFS. High expression levels of MAGEA5 in the basal-like 1 subtype (HR, 0.60; 95% CI, 0.37--0.96; P=0.0327); MAGEB6 (HR, 0.43; 95% CI, 0.19--0.97; P=0.0356), MAGED2 (HR, 0.46; 95% CI, 0.23--0.95; P=0.0308), MAGEE1 (HR, 0.25; 95% CI, 0.07--0.85; P=0.0160), MAGEF1 (HR 0.33; 95% CI, 0.14--0.81; P=0.0110) in the basal-like 2 subtype; MAGEB6 (HR, 0.41; 95% CI, 0.17--0.96; P=0.0333) in the immunomodulatory subtype; MAGEA8 (HR, 0.60; 95% CI, 0.38--0.95; P=0.0268), MAGEB6 (HR, 0.47; 95% CI, 0.24--0.89; P=0.0181), MAGEL2 (HR, 0.62; 95% CI, 0.39--0.99; P=0.0433) in the mesenchymal subtype; MAGEA8 (HR, 0.41; 95% CI, 0.18--0.93; P=0.0280), MAGEC3 (HR, 0.32; 95% CI, 0.12--0.85; P=0.0159), MAGEE2 (HR, 0.34; 95% CI, 0.12--0.97; P=0.0345), MAGEF1 (HR, 0.41; 95% CI, 0.18--0.94; P=0.0292) in the mesenchymal stem-like subtype; and MAGEA5 (HR, 0.62; 95% CI, 0.41--0.93; P=0.0195), MAGEB4 (HR, 0.64; 95% CI, 0.41--1.00; P=0.0471), MAGEF1 (HR, 0.61; 95% CI, 0.41--0.91; P=0.0158) and MAGEL2 (HR, 0.61; 95% CI, 0.41--0.93; P=0.0188) in the luminal androgen receptor breast cancer subtype were significantly associated with improved RFS. However, high mRNA expression levels of MAGEH1 (HR, 1.87; 95% CI, 1.16--3.02; P=0.0090) in the basal-like 1 subtype; MAGED3 (HR, 2.93; 95% CI, 1.34--6.39; P=0.0047) in the basal-like 2 subtype; MAGEA5 (HR, 1.81; 95% CI, 1.17--2.79; P=0.0066) in the mesenchymal subtype; and MAGEH1 (HR, 1.72; 95% CI, 1.15--2.59; P=0.0079) in the luminal androgen receptor breast cancer subtype were significantly associated with worse RFS. High mRNA expression levels of MAGED2 (HR, 1.68; 95% CI, 1.02--2.77; P=0.0386), MAGED4 (HR, 1.61; 95% CI, 1.00--2.59; P=0.0494) in the basal-like 1 subtype; MAGEB4 (HR, 2.74; 95% CI, 1.22--6.14; P=0.0106) and MAGEH1 (HR, 2.17; 95% CI, 1.06--4.40; P=0.0288) in the basal-like 2 subtype; MAGEB18 (HR, 2.39; 95% CI, 1.03--5.51; P=0.0353) and MAGEH1 (HR, 1.89; 95% CI, 1.05--3.42; P=0.0314) in the immunomodulatory subtype; MAGED3 (HR, 1.59; 95% CI, 1.04--2.43; P=0.0317), MAGEE1 (HR, 1.82; 95% CI, 1.06--3.15; P=0.0284) and MAGEH1 (HR, 1.56; 95% CI, 1.01--2.42; P=0.0421) in the mesenchymal subtype; MAGED4 (HR, 3.16; 95% CI, 0.94--10.56; P=0.0488) in the mesenchymal stem-like subtype; and MAGEB18 (HR, 2.04; 95% CI, 1.11--3.77; P=0.0211) and MAGED4 (HR, 1.59; 95% CI, 1.05--2.40; P=0.0267) in the luminal androgen receptor breast cancer subtype were significantly associated with worse RFS.

Discussion
==========

Breast cancer, which is one of the most common malignant tumors, was the second leading cause of cancer-associated mortality among women worldwide in the year 2017 ([@b1-ol-0-0-10722],[@b2-ol-0-0-10722]). MAGE gene family members have been demonstrated to be expressed in male germ line and placental cells, as well as in a number of different tumor types, including melanoma, brain, lung, prostate and breast cancer ([@b31-ol-0-0-10722],[@b32-ol-0-0-10722]). The aberrant expression levels of the MAGE family members have been demonstrated to be associated with progressive disease; however, the mechanisms underlying how individual MAGE family members contribute to disease occurrence are largely unknown ([@b33-ol-0-0-10722]). In addition, to the best of our knowledge, many of these genes have not been reported in breast cancer.

In the present study, high mRNA expression levels of MAGEA5 were significantly associated with improved prognosis in luminal and basal-like breast cancer subtypes, and significantly associated with worse RFS in lymph node-positive breast cancer. In addition, high mRNA expression levels of MAGEA8 were significantly associated with improved prognosis in luminal and basal-like breast cancer subtypes, as well as HER2^+^ breast cancer. Previously, there have been few reports regarding the genes MAGEA5 and MAGEA8 in breast cancer, despite other members of the MAGEA family being investigated in this disease. Raghavendra *et al* ([@b34-ol-0-0-10722]) revealed that MAGEA1 is frequently expressed in triple-negative breast cancer, and Park *et al* ([@b35-ol-0-0-10722]) demonstrated that MAGEA2 promotes the progression of breast cancer by regulating the Akt and Erk1/2 pathways. Taylor *et al* ([@b36-ol-0-0-10722]) suggested that a vaccine that targets MAGEA10 may be of potential use in ≤70% of breast cancers. Abd-Elsalam and Ismaeil ([@b37-ol-0-0-10722]) reported that measuring the expression levels of the gene MAGEA1-A6 and MAGEA12 at the same time may aid in monitoring the effectiveness of breast cancer therapy. Through a comprehensive analysis, MAGEA5 and MAGEA8 were predicted to serve a protective role in the occurrence and development of breast cancer in the present study.

The administration of a MAGEB vaccination to elderly mice (20 months) leads to the absence of CD8 T-cell responses and reduced protection against metastatic breast cancer ([@b38-ol-0-0-10722]). In the present study, high mRNA expression levels of MAGEB4 and MAGEB6 were significantly associated with improved RFS in all breast cancer subtypes; high MAGEB6 expression was significantly associated with improved RFS in lymph node-negative, tumor grades I and III, but was also associated with worse RFS in TP53 wild-type breast cancer. High mRNA expression levels of MAGEB4 were significantly associated with improved RFS in TP53-mutated breast cancer, but also with worse RFS in grade I breast cancer. MAGEB18 was moderately associated with worse RFS in all breast cancer, and in immunomodulatory and luminal androgen receptor breast cancer subtypes. Previous studies have demonstrated that MAGEB4 may be a potential biomarker in patients with transitional cell carcinoma ([@b39-ol-0-0-10722]), and that it is specifically expressed during germ cell differentiation ([@b40-ol-0-0-10722]). The mRNA-positivity expression of MAGEB6 is associated with a poor prognosis in patients with head and neck squamous cell carcinoma ([@b41-ol-0-0-10722]), and the mouse MAGEB18 gene encodes a ubiquitously expressed type I MAGE protein, and regulates cell proliferation and apoptosis in melanoma B16-F0 cells ([@b42-ol-0-0-10722]). Overall, to the best of our knowledge, there are currently no published studies that demonstrate the function of the MAGE family members in breast cancer, and only a small number of studies that indicate their association with other diseases. Following a detailed database analysis, MAGEB18 was predicted to have a damaging effect on the occurrence and development of breast cancer in the present study. Despite the contrasting prognostic effects of MAGEB4 and MAGEB6 in the different types of breast cancer, it could be suggested that these two molecules are more likely to serve roles as tumor suppressor genes, according to the results from the present study. Further investigation is required to verify this suggestion.

MAGEC was also analyzed in the present study. It was revealed that high mRNA expression levels of MAGEC3 were significantly associated with improved RFS in luminal, basal, HER2^+^, tumor grade II and mesenchymal stem-like breast cancer subtypes. Eng *et al* ([@b43-ol-0-0-10722]) indicated that MAGEC3 may be associated with earlier onset of ovarian cancer. Bao *et al* ([@b44-ol-0-0-10722]) used a single-cell sample of \>100 pairs of primary breast cancer and corresponding metastatic lymph node samples to perform whole exome and deep-target sequencing analyses, and revealed that MAGEC3 is associated with lymph node metastasis in patients with breast cancer. In the present study it was demonstrated that high mRNA expression levels of MAGEC3 were associated with worse RFS in lymph node-status (positive) breast cancer, but were also associated with improved RFS in lymph node-status (negative)breast cancer; however, these results were not statistically significant. These results provided further support for the hypothesis that MAGEC3 may promote cell metastasis in breast cancer, particularly lymph node metastasis.

High mRNA expression levels of MAGED2 and MAGED3 were significantly associated with improved RFS in all breast cancer. High mRNA expression levels of MAGED2 were significantly associated with improved RFS in lymph node-positive and -negative breast cancer, as well as in the basal-like 2 breast cancer subtype; in contrast, high mRNA expression levels of MAGED2 were associated with worse RFS in HER2^+^, all basal-like, TP53-mutated, tumor grade III and basal-like 1 breast cancer subtype; high mRNA expression levels of MAGED3 were significantly associated with improved RFS in luminal, lymph node-positive and TP53-mutated breast cancer, but also with worse RFS in basal-like 2 subtype, mesenchymal subtype and tumor grade III breast cancer. High mRNA expression levels of MAGED4 were significantly associated with worse RFS in lymph node-positive and -negative, TP53 wild-type, basal-like 1, mesenchymal stem-like, luminal androgen receptor breast cancer, and all breast cancer. A previous study revealed that MAGED2 is able to control cell cycle progression and modulate the DNA damage response ([@b45-ol-0-0-10722]), and that increased expression of MAGED2 is associated with nodal and hematogenous metastasis and is an independent prognostic factor for gastric cancer ([@b26-ol-0-0-10722],[@b46-ol-0-0-10722]). Zhang *et al* ([@b47-ol-0-0-10722]) reported that MAGED4 is frequently and highly expressed in glioma, and is partly regulated by DNA methylation. Ma *et al* ([@b48-ol-0-0-10722]) reported that MAGED4 may be used as a specific antigen for non-small cell lung cancer to influence the improvement of diagnosis, prognosis and immunological therapy outcomes in patients with lung cancer. According to these data, it was predicted that MAGED4 may be a cancer-promoting gene in breast cancer; however, MAGED2 and MAGED3 may have different effects depending on the type of breast cancer.

High mRNA expression levels of MAGEE1 were significantly associated with improved RFS in grade I and basal-like 2 breast cancer, but also with worse RFS in grade III and mesenchymal breast cancer; high mRNA expression levels of MAGEE2 were significantly associated with improved RFS in basal, lymph node-negative and mesenchymal stem-like breast cancer, but also with worse RFS in TP53 wild-type breast cancer. MAGEE2 expression has been reported to be associated with poor OS in The Cancer Genome Atlas human breast cancer cohort (n=1,082) ([@b49-ol-0-0-10722]). In general, these findings indicated that MAGEE2 was closely associated with the occurrence and development of breast cancer, particularly in TP53 wild-type breast cancer. However, whether MAGEE2 can be used as a prognostic factor requires further investigation.

High mRNA expression levels of MAGEF1 were significantly associated with improved RFS in basal, lymph node-positive, grade II, basal-like 2, mesenchymal stem-like and luminal androgen receptor breast cancer, but also with worse RFS in lymph node-negative, TP53-mutated and TP53 wild-type breast cancer. Stone *et al* ([@b50-ol-0-0-10722]) demonstrated that MAGEF1 is ubiquitously expressed in normal tissues, as well as in melanoma, leukemia, ovarian and cervical tumor tissues and cell lines. It is possible, therefore, that the mechanism underlying MAGEF1 in these different types of breast cancer varies, but whether MAGEF1 can be used as a prognostic factor in TP53-mutated or wild-type patients requires further investigation.

Finally, high mRNA expression levels of MAGEH1 were significantly associated with worse RFS in luminal B, HER2^+^, basal, basal-like 1 and luminal androgen receptor breast cancer subtypes, but also with improved RFS in tumor grades I and II breast cancer. High mRNA expression levels of MAGEL2 were significantly associated with improved RFS in luminal A breast cancer subtypes, but also with worse RFS in tumor grade III breast cancer. Wang *et al* ([@b51-ol-0-0-10722]) demonstrated that MAGEH1 enhances hepatocellular carcinoma progression and serves as a biomarker for patient prognosis, whereas Ojima *et al* ([@b52-ol-0-0-10722]) revealed that negative expression (anti-MAGEH1) of the MAGEH1 protein serves as a potential predictive marker for the effectiveness of gemcitabine therapy in biliary tract carcinoma. These findings, while preliminary, suggested that MAGEH1 and MAGEL2 have effects in breast cancer patients with different pathological grades.

Despite obtaining a number of useful insights in the present study, there were some limitations. Firstly, the roles that the selected members of the MAGE family serve in breast cancer were demonstrated using bioinformatics analyses only. Secondly, the underlying molecular mechanisms were not identified. Thus, more in-depth investigations *in vitro* and *in vivo* are required in order to verify the conclusions drawn within the present study.

In summary, the prognostic value of the mRNA expression levels of 29 members of the MAGE family were analyzed in patients with breast cancer using the Kaplan-Meier plotter database. Through searching PubMed and other database, among these 29 members, 14 members were significantly associated with the prognosis of patients with breast cancer. Further investigation regarding the prognostic values of the MAGE family members in breast cancer with different clinical features suggested that MAGEA5, MAGEA8, MAGEB4 and MAGEB6 may have protective roles in the occurrence and development of breast cancer, whereas MAGEB18 and MAGED4 may possess carcinogenic effects. MAGED2, MAGED3 and MAGEF1 incur different effects depending on the type of breast cancer. It is worth noting that MAGEC3 may promote cell metastasis in breast cancer, particularly lymph node metastasis. Whether MAGEE2, MAGEH1 and MAGEL2 may be used as prognostic factors in TP53 wild-type breast cancer, as well as in the different pathological grades of breast cancer requires further study.

The present study provided novel insights regarding the contribution of the MAGE family members to breast cancer progression and may aid in the discovery of MAGE-target inhibitors for treating breast cancer.
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MAGE

:   melanoma-associated antigen

GEO

:   Gene Expression Omnibus

RFS

:   relapse-free survival

OS

:   overall survival

DMFS

:   distant metastasis-free survival

PPS

:   post-progression survival

HR

:   hazard ratio

CI

:   confidence interval

###### 

Prognostic value of the mRNA expression levels of the MAGE family members using the Kaplan-Meier plotter database. (A) Prognostic HRs of individual MAGE family members in all types of breast cancer. Red indicates HR≥1, green indicates HR\<1 and black indicates HR (0.99--1.23). (B) Kaplan-Meier survival curves of the mRNA expression levels of MAGE family members. 1, MAGEA1; 2, MAGEA2; 3, MAGEA3; 4, MAGEA4; 5, MAGEA5; 6, MAGEA6; 7, MAGEA8; 8, MAGEA9; 9, MAGEA10; 10, MAGEA11; and-11, MAGEA12 for all breast cancer patients (n=3,955). All BC, all breast cancer; HR, hazard ratio; MAGE, melanoma-associated antigen. (C) Kaplan-Meier survival curves of the mRNA expression levels of MAGE family members. 1, MAGEB1; 2, MAGEB2; 3, MAGEB3; 4, MAGEB4; 5, MAGEB6; 6, MAGEB18; 7, MAGEC1; 8, MAGEC2; 9, MAGEC3; 10, MAGED1; 11, MAGED2; 12, MAGED3; 13, MAGED4; 14, MAGEE1; 15, MAGEE2; 16, MAGEF1; 17, MAGEH1; and 18, MAGEL2 for all breast cancer patients (n=3,955). All BC, all breast cancer; HR, hazard ratio; MAGE, melanoma-associated antigen.
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![Kaplan-Meier survival curves of the mRNA expression levels of (A) MAGEA5, (B) MAGEA8, (C) MAGEB4, (D) MAGEB6, (E) MAGEC3, (F) MAGED2, (G) MAGEE2, (H) MAGEF1 and (I) MAGEH1 for patients with basal-like breast cancer subtypes (n=879). HR, hazard ratio; MAGE, melanoma-associated antigen.](ol-18-04-3501-g03){#f2-ol-0-0-10722}

![Kaplan-Meier survival curves of the mRNA expression levels of (A) MAGEA5, (B) MAGEA8, (C) MAGEB4, (D) MAGEC3, (E) MAGED3, (F) MAGEE1, (G) MAGEF1, (H) MAGEH1 and (I) MAGEL2 for patients with the luminal A breast cancer subtype (n=2,504). HR, hazard ratio; MAGE, melanoma-associated antigen.](ol-18-04-3501-g04){#f3-ol-0-0-10722}

![Kaplan-Meier survival curves of the mRNA expression levels of (A) MAGEA5, (B) MAGEA8, (C) MAGEB4, (D) MAGEB18, (E) MAGEC3, (F) MAGED3, (G) MAGEE1, (H) MAGEH1 and (I) MAGEL2 for patients with the luminal B breast cancer subtype (n=1,425). HR, hazard ratio; MAGE, melanoma-associated antigen.](ol-18-04-3501-g05){#f4-ol-0-0-10722}

![Kaplan-Meier survival curves of the mRNA expression levels of (A) MAGEA8, (B) MAGEC3, (C) MAGED2 and (D) MAGEH1 for patients with the HER2+ breast cancer subtype (n=335). HER2, human epidermal growth factor receptor 2; HR, hazard ratio; MAGE, melanoma-associated antigen.](ol-18-04-3501-g06){#f5-ol-0-0-10722}

###### 

Associations between the different MAGE family members and positive or negative lymph node status of patients with breast cancer.

  MAGE family member   Affymetrix ID   Lymph node status   HR                                                   95% CI                                                     P-value
  -------------------- --------------- ------------------- ---------------------------------------------------- ---------------------------------------------------------- ------------------------------------------------------
  MAGEA5               214642_x\_at    Positive            1.24^[b](#tfn3-ol-0-0-10722){ref-type="table-fn"}^   1.00--1.53^[b](#tfn3-ol-0-0-10722){ref-type="table-fn"}^   0.0447^[b](#tfn3-ol-0-0-10722){ref-type="table-fn"}^
                                       Negative            0.90                                                 0.76--1.06                                                 0.2129
  MAGEA8               210274_at       Positive            1.22                                                 0.99--1.52                                                 0.0646
                                       Negative            0.85                                                 0.71--1.03                                                 0.0946
  MAGEB4               207580_at       Positive            1.18                                                 0.95--1.48                                                 0.1385
                                       Negative            0.87                                                 0.72--1.06                                                 0.1809
  MAGEB6               1552858_at      Positive            0.78                                                 0.60--1.00                                                 0.0515
                                       Negative            0.55^[a](#tfn2-ol-0-0-10722){ref-type="table-fn"}^   0.33--0.91^[a](#tfn2-ol-0-0-10722){ref-type="table-fn"}^   0.0188^[a](#tfn2-ol-0-0-10722){ref-type="table-fn"}^
  MAGEB18              1552913_at      Positive            0.84                                                 0.65--1.09                                                 0.1869
                                       Negative            1.47                                                 0.98--2.21                                                 0.0601
  MAGEC3               216592_at       Positive            1.20                                                 0.98--1.48                                                 0.0810
                                       Negative            0.85                                                 0.71--1.01                                                 0.0640
  MAGED2               213627_at       Positive            0.79^[a](#tfn2-ol-0-0-10722){ref-type="table-fn"}^   0.65--0.96^[a](#tfn2-ol-0-0-10722){ref-type="table-fn"}^   0.0200^[a](#tfn2-ol-0-0-10722){ref-type="table-fn"}^
                                       Negative            0.82^[a](#tfn2-ol-0-0-10722){ref-type="table-fn"}^   0.68--0.99^[a](#tfn2-ol-0-0-10722){ref-type="table-fn"}^   0.0400^[a](#tfn2-ol-0-0-10722){ref-type="table-fn"}^
  MAGED3               205028_at       Positive            0.81^[a](#tfn2-ol-0-0-10722){ref-type="table-fn"}^   0.67--0.99^[a](#tfn2-ol-0-0-10722){ref-type="table-fn"}^   0.0390^[a](#tfn2-ol-0-0-10722){ref-type="table-fn"}^
                                       Negative            1.10                                                 0.93--1.30                                                 0.2800
  MAGED4               221261_x\_at    Positive            1.24^[b](#tfn3-ol-0-0-10722){ref-type="table-fn"}^   1.02--1.51^[b](#tfn3-ol-0-0-10722){ref-type="table-fn"}^   0.0290^[b](#tfn3-ol-0-0-10722){ref-type="table-fn"}^
                                       Negative            1.27^[b](#tfn3-ol-0-0-10722){ref-type="table-fn"}^   1.07--1.51^[b](#tfn3-ol-0-0-10722){ref-type="table-fn"}^   0.0062^[b](#tfn3-ol-0-0-10722){ref-type="table-fn"}^
  MAGEE1               1556047_s\_at   Positive            0.81                                                 0.62--1.04                                                 0.1013
                                       Negative            0.79                                                 0.54--1.17                                                 0.2400
  MAGEE2               1553254_at      Positive            1.23                                                 0.95--1.58                                                 0.1096
                                       Negative            0.57^[a](#tfn2-ol-0-0-10722){ref-type="table-fn"}^   0.33--0.98^[a](#tfn2-ol-0-0-10722){ref-type="table-fn"}^   0.0376^[a](#tfn2-ol-0-0-10722){ref-type="table-fn"}^
  MAGEF1               218176_at       Positive            0.75^[a](#tfn2-ol-0-0-10722){ref-type="table-fn"}^   0.61--0.93^[a](#tfn2-ol-0-0-10722){ref-type="table-fn"}^   0.0094^[a](#tfn2-ol-0-0-10722){ref-type="table-fn"}^
                                       Negative            1.26^[b](#tfn3-ol-0-0-10722){ref-type="table-fn"}^   1.07--1.50^[b](#tfn3-ol-0-0-10722){ref-type="table-fn"}^   0.0063^[b](#tfn3-ol-0-0-10722){ref-type="table-fn"}^
  MAGEH1               218573_at       Positive            1.30^[b](#tfn3-ol-0-0-10722){ref-type="table-fn"}^   1.04--1.62^[b](#tfn3-ol-0-0-10722){ref-type="table-fn"}^   0.0185^[b](#tfn3-ol-0-0-10722){ref-type="table-fn"}^
                                       Negative            0.91                                                 0.75--1.11                                                 0.3438
  MAGEL2               219894_at       Positive            1.08                                                 0.88--1.31                                                 0.4600
                                       Negative            0.83^[a](#tfn2-ol-0-0-10722){ref-type="table-fn"}^   0.69--1.00^[a](#tfn2-ol-0-0-10722){ref-type="table-fn"}^   0.0464^[a](#tfn2-ol-0-0-10722){ref-type="table-fn"}^

P\<0.05 was considered to indicate a statistically significant difference.

High mRNA expression levels associated with improved RFS

high mRNA expression levels associated with worse RFS. Total patients assigned a lymph node status, n=3,718; lymph node-positive patients, n=1,459; lymph node-negative patients, n=2,259, analyzed by ANOVA. CI, confidence interval; HR, hazard ratio; MAGE, melanoma-associated antigen; RFS, relapse-free survival.

###### 

Association between the MAGE family members and pathological tumor grade of patients with breast cancer.

  MAGE family member   Affymetrix ID   Tumor grade   HR                                                   95% CI                                                     P-value
  -------------------- --------------- ------------- ---------------------------------------------------- ---------------------------------------------------------- ------------------------------------------------------
  MAGEA5               214642_at       I             0.72                                                 0.43--1.22                                                 0.2269
                                       II            1.27                                                 0.95--1.68                                                 0.1038
                                       III           1.12                                                 0.88--1.43                                                 0.3578
  MAGEA8               210274_at       I             0.63                                                 0.33--1.22                                                 0.1702
                                       II            0.74^[a](#tfn5-ol-0-0-10722){ref-type="table-fn"}^   0.57--0.96^[a](#tfn5-ol-0-0-10722){ref-type="table-fn"}^   0.0248^[a](#tfn5-ol-0-0-10722){ref-type="table-fn"}^
                                       III           0.78^[a](#tfn5-ol-0-0-10722){ref-type="table-fn"}^   0.61--0.99^[a](#tfn5-ol-0-0-10722){ref-type="table-fn"}^   0.0373^[a](#tfn5-ol-0-0-10722){ref-type="table-fn"}^
  MAGEB4               207580_at       I             1.91^[b](#tfn6-ol-0-0-10722){ref-type="table-fn"}^   1.06--3.43^[b](#tfn6-ol-0-0-10722){ref-type="table-fn"}^   0.0288^[b](#tfn6-ol-0-0-10722){ref-type="table-fn"}^
                                       II            0.79                                                 0.60--1.02                                                 0.0732
                                       III           0.72^[a](#tfn5-ol-0-0-10722){ref-type="table-fn"}^   0.58--0.90^[a](#tfn5-ol-0-0-10722){ref-type="table-fn"}^   0.0041^[a](#tfn5-ol-0-0-10722){ref-type="table-fn"}^
  MAGEB6               1552858_at      I             0.29^[a](#tfn5-ol-0-0-10722){ref-type="table-fn"}^   0.10--0.83^[a](#tfn5-ol-0-0-10722){ref-type="table-fn"}^   0.0136^[a](#tfn5-ol-0-0-10722){ref-type="table-fn"}^
                                       II            1.19                                                 0.72--1.99                                                 0.4982
                                       III           0.62^[a](#tfn5-ol-0-0-10722){ref-type="table-fn"}^   0.46--0.85^[a](#tfn5-ol-0-0-10722){ref-type="table-fn"}^   0.0029^[a](#tfn5-ol-0-0-10722){ref-type="table-fn"}^
  MAGEB18              1552913_at      I             3.46^[b](#tfn6-ol-0-0-10722){ref-type="table-fn"}^   1.20--9.98^[b](#tfn6-ol-0-0-10722){ref-type="table-fn"}^   0.0142^[b](#tfn6-ol-0-0-10722){ref-type="table-fn"}^
                                       II            1.65                                                 0.93--2.93                                                 0.0840
                                       III           1.27                                                 0.90--1.78                                                 0.1706
  MAGEC3               216592_at       I             1.51                                                 0.80--2.85                                                 0.2000
                                       II            0.74^[a](#tfn5-ol-0-0-10722){ref-type="table-fn"}^   0.57--0.96^[a](#tfn5-ol-0-0-10722){ref-type="table-fn"}^   0.0210^[a](#tfn5-ol-0-0-10722){ref-type="table-fn"}^
                                       III           0.89                                                 0.71--1.11                                                 0.2900
  MAGED2               213627_at       I             1.47                                                 0.87--2.48                                                 0.1500
                                       II            0.86                                                 0.67--1.10                                                 0.2200
                                       III           1.39^[b](#tfn6-ol-0-0-10722){ref-type="table-fn"}^   1.11--1.73^[b](#tfn6-ol-0-0-10722){ref-type="table-fn"}^   0.0042^[b](#tfn6-ol-0-0-10722){ref-type="table-fn"}^
  MAGED3               205028_at       I             1.64                                                 0.95--2.83                                                 0.0720
                                       II            0.79                                                 0.62--1.01                                                 0.0620
                                       III           1.35^[b](#tfn6-ol-0-0-10722){ref-type="table-fn"}^   1.07--1.69^[b](#tfn6-ol-0-0-10722){ref-type="table-fn"}^   0.0101^[b](#tfn6-ol-0-0-10722){ref-type="table-fn"}^
  MAGED4               221261_x\_at    I             0.54                                                 0.26--1.10                                                 0.0827
                                       II            1.52^[b](#tfn6-ol-0-0-10722){ref-type="table-fn"}^   1.18--1.95^[b](#tfn6-ol-0-0-10722){ref-type="table-fn"}^   0.0009^[b](#tfn6-ol-0-0-10722){ref-type="table-fn"}^
                                       III           1.20                                                 0.97--1.50                                                 0.0946
  MAGEE1               1556047_s\_at   I             0.35^[a](#tfn5-ol-0-0-10722){ref-type="table-fn"}^   0.12--1.02^[a](#tfn5-ol-0-0-10722){ref-type="table-fn"}^   0.0435^[a](#tfn5-ol-0-0-10722){ref-type="table-fn"}^
                                       II            0.61                                                 0.35--1.05                                                 0.0730
                                       III           1.53^[b](#tfn6-ol-0-0-10722){ref-type="table-fn"}^   1.12--2.08^[b](#tfn6-ol-0-0-10722){ref-type="table-fn"}^   0.0075^[b](#tfn6-ol-0-0-10722){ref-type="table-fn"}^
  MAGEE2               1553254_at      I             0.56                                                 0.19--1.67                                                 0.2903
                                       II            1.22                                                 0.73--2.04                                                 0.4500
                                       III           1.18                                                 0.87--1.61                                                 0.2900
  MAGEF1               218176_at       I             0.67                                                 0.36--1.24                                                 0.1993
                                       II            0.70^[a](#tfn5-ol-0-0-10722){ref-type="table-fn"}^   0.54--0.90^[a](#tfn5-ol-0-0-10722){ref-type="table-fn"}^   0.0057^[a](#tfn5-ol-0-0-10722){ref-type="table-fn"}^
                                       III           0.85                                                 0.67--1.08                                                 0.1788
  MAGEH1               218573_at       I             0.52^[a](#tfn5-ol-0-0-10722){ref-type="table-fn"}^   0.30--0.88^[a](#tfn5-ol-0-0-10722){ref-type="table-fn"}^   0.0140^[a](#tfn5-ol-0-0-10722){ref-type="table-fn"}^
                                       II            0.63^[a](#tfn5-ol-0-0-10722){ref-type="table-fn"}^   0.47--0.85^[a](#tfn5-ol-0-0-10722){ref-type="table-fn"}^   0.0020^[a](#tfn5-ol-0-0-10722){ref-type="table-fn"}^
                                       III           1.18                                                 0.94--1.49                                                 0.1600
  MAGEL2               219894_at       I             0.71                                                 0.42--1.19                                                 0.1907
                                       II            0.79                                                 0.62--1.00                                                 0.0513
                                       III           1.25^[b](#tfn6-ol-0-0-10722){ref-type="table-fn"}^   1.01--1.56^[b](#tfn6-ol-0-0-10722){ref-type="table-fn"}^   0.0420^[b](#tfn6-ol-0-0-10722){ref-type="table-fn"}^

P\<0.05 was considered to indicate a statistically significant difference.

High mRNA expression levels associated with improved RFS

high mRNA expression levels associated with worse RFS. Total patients with a pathological tumor grade, n=2,545; patients with tumor grade I, n=378; patients with tumor grade II, n=1,077; patients with tumor grade III, n=1,090 patients. CI, confidence interval; HR, hazard ratio; MAGE, melanoma-associated antigen; RFS, relapse-free survival.

###### 

Association between MAGE family members and the TP53 status of patients with breast cancer.

  MAGE family member   Affymetrix ID   TP53 status   HR                                                   95% CI                                                      P-value
  -------------------- --------------- ------------- ---------------------------------------------------- ----------------------------------------------------------- ------------------------------------------------------
  MAGEA5               214642_at       Mutated       1.38                                                 0.81--2.37                                                  0.2357
                                       Wild-type     1.39                                                 0.88--2.17                                                  0.1236
  MAGEA8               210274_at       Mutated       0.69                                                 0.43--1.12                                                  0.1317
                                       Wild-type     0.80                                                 0.50--1.27                                                  0.3462
  MAGEB4               207580_at       Mutated       0.53^[a](#tfn8-ol-0-0-10722){ref-type="table-fn"}^   0.31--0.88^[a](#tfn8-ol-0-0-10722){ref-type="table-fn"}^    0.0136^[a](#tfn8-ol-0-0-10722){ref-type="table-fn"}^
                                       Wild-type     0.78                                                 0.51--1.20                                                  0.2634
  MAGEB6               1552858_at      Mutated       0.64                                                 0.34--1.18                                                  0.1506
                                       Wild-type     5.08^[b](#tfn9-ol-0-0-10722){ref-type="table-fn"}^   1.18--21.89^[b](#tfn9-ol-0-0-10722){ref-type="table-fn"}^   0.0157
  MAGEB18              1552913_at      Mutated       0.66                                                 0.35--1.24                                                  0.1931
                                       Wild-type     3.51^[b](#tfn9-ol-0-0-10722){ref-type="table-fn"}^   1.50--8.22^[b](#tfn9-ol-0-0-10722){ref-type="table-fn"}^    0.0021^[b](#tfn9-ol-0-0-10722){ref-type="table-fn"}^
  MAGEC3               216592_at       Mutated       0.75                                                 0.46--1.23                                                  0.2500
                                       Wild-type     0.85                                                 0.56--1.31                                                  0.4700
  MAGED2               213627_at       Mutated       2.10^[b](#tfn9-ol-0-0-10722){ref-type="table-fn"}^   1.28--3.46^[b](#tfn9-ol-0-0-10722){ref-type="table-fn"}^    0.0028^[b](#tfn9-ol-0-0-10722){ref-type="table-fn"}^
                                       Wild-type     0.80                                                 0.53--1.23                                                  0.3100
  MAGED3               205028_at       Mutated       0.59^[a](#tfn8-ol-0-0-10722){ref-type="table-fn"}^   0.37--0.95^[a](#tfn8-ol-0-0-10722){ref-type="table-fn"}^    0.0280^[a](#tfn8-ol-0-0-10722){ref-type="table-fn"}^
                                       Wild-type     0.74                                                 0.45--1.21                                                  0.2286
  MAGED4               221261_x\_at    Mutated       0.71                                                 0.44--1.14                                                  0.1513
                                       Wild-type     1.82^[b](#tfn9-ol-0-0-10722){ref-type="table-fn"}^   1.18--2.83^[b](#tfn9-ol-0-0-10722){ref-type="table-fn"}^    0.0065^[b](#tfn9-ol-0-0-10722){ref-type="table-fn"}^
  MAGEE1               1556047_s\_at   Mutated       1.76                                                 0.96--3.25                                                  0.0660
                                       Wild-type     0.48                                                 0.19--1.23                                                  0.1200
  MAGEE2               1553254_at      Mutated       0.54                                                 0.25--1.17                                                  0.1138
                                       Wild-type     2.35^[b](#tfn9-ol-0-0-10722){ref-type="table-fn"}^   1.01--5.48^[b](#tfn9-ol-0-0-10722){ref-type="table-fn"}^    0.0414^[b](#tfn9-ol-0-0-10722){ref-type="table-fn"}^
  MAGEF1               218176_at       Mutated       1.68^[b](#tfn9-ol-0-0-10722){ref-type="table-fn"}^   1.04--2.71^[b](#tfn9-ol-0-0-10722){ref-type="table-fn"}^    0.0318^[b](#tfn9-ol-0-0-10722){ref-type="table-fn"}^
                                       Wild-type     1.65^[b](#tfn9-ol-0-0-10722){ref-type="table-fn"}^   1.06--2.55^[b](#tfn9-ol-0-0-10722){ref-type="table-fn"}^    0.0240^[b](#tfn9-ol-0-0-10722){ref-type="table-fn"}^
  MAGEH1               218573_at       Mutated       1.60                                                 0.98--2.64                                                  0.0600
                                       Wild-type     0.67                                                 0.44--1.04                                                  0.0710
  MAGEL2               219894_at       Mutated       1.58                                                 0.95--2.64                                                  0.0777
                                       Wild-type     0.58^[a](#tfn8-ol-0-0-10722){ref-type="table-fn"}^   0.34--0.99^[a](#tfn8-ol-0-0-10722){ref-type="table-fn"}^    0.0430^[a](#tfn8-ol-0-0-10722){ref-type="table-fn"}^

P\<0.05 was considered to indicate a statistically significant difference.

High mRNA expression levels associated with improved RFS

high mRNA expression levels associated with worse RFS. Total patients assigned a TP53 status, n=595; patients with TP53-mutated breast cancer, n=232; patients with wild-type TP53 breast cancer, n=363. CI, confidence interval; HR, hazard ratio; MAGE, melanoma-associated antigen; RFS, relapse-free survival.

###### 

Association between the MAGE family members and different Pietenpol subtypes of patients with breast cancer.

  MAGE family member   Affymetrix ID   Pietenpol subtype           HR                                                    95% CI                                                       P-value
  -------------------- --------------- --------------------------- ----------------------------------------------------- ------------------------------------------------------------ -------------------------------------------------------
  MAGEA5               214642_at       Basal-like 1                0.60^[a](#tfn11-ol-0-0-10722){ref-type="table-fn"}^   0.37--0.96^[a](#tfn11-ol-0-0-10722){ref-type="table-fn"}^    0.0327^[a](#tfn11-ol-0-0-10722){ref-type="table-fn"}^
                                       Basal-like 2                1.71                                                  0.84--3.46                                                   0.1324
                                       Immunomodulatory            1.48                                                  0.73--2.99                                                   0.2723
                                       Mesenchymal                 1.81^[b](#tfn12-ol-0-0-10722){ref-type="table-fn"}^   1.17--2.79^[b](#tfn12-ol-0-0-10722){ref-type="table-fn"}^    0.0066^[b](#tfn12-ol-0-0-10722){ref-type="table-fn"}^
                                       Mesenchymal stem-like       2.62                                                  0.78--8.76                                                   0.1041
                                       Luminal androgen receptor   0.62^[a](#tfn11-ol-0-0-10722){ref-type="table-fn"}^   0.41--0.93^[a](#tfn11-ol-0-0-10722){ref-type="table-fn"}^    0.0195^[a](#tfn11-ol-0-0-10722){ref-type="table-fn"}^
  MAGEA8               210274_at       Basal-like 1                0.50^[a](#tfn11-ol-0-0-10722){ref-type="table-fn"}^   0.31--0.83^[a](#tfn11-ol-0-0-10722){ref-type="table-fn"}^    0.0059^[a](#tfn11-ol-0-0-10722){ref-type="table-fn"}^
                                       Basal-like 2                1.51                                                  0.75--3.06                                                   0.2499
                                       Immunomodulatory            1.36                                                  0.71--2.61                                                   0.3555
                                       Mesenchymal                 0.60^[a](#tfn11-ol-0-0-10722){ref-type="table-fn"}^   0.38--0.95^[a](#tfn11-ol-0-0-10722){ref-type="table-fn"}^    0.0268^[a](#tfn11-ol-0-0-10722){ref-type="table-fn"}^
                                       Mesenchymal stem-like       0.41^[a](#tfn11-ol-0-0-10722){ref-type="table-fn"}^   0.18--0.93^[a](#tfn11-ol-0-0-10722){ref-type="table-fn"}^    0.0280^[a](#tfn11-ol-0-0-10722){ref-type="table-fn"}^
                                       Luminal androgen receptor   0.52^[a](#tfn11-ol-0-0-10722){ref-type="table-fn"}^   0.31--0.85^[a](#tfn11-ol-0-0-10722){ref-type="table-fn"}^    0.0076^[a](#tfn11-ol-0-0-10722){ref-type="table-fn"}^
  MAGEB4               207580_at       Basal-like 1                0.60                                                  0.36--1.02                                                   0.0550
                                       Basal-like 2                2.74^[b](#tfn12-ol-0-0-10722){ref-type="table-fn"}^   1.22--6.14^[b](#tfn12-ol-0-0-10722){ref-type="table-fn"}^    0.0106^[b](#tfn12-ol-0-0-10722){ref-type="table-fn"}^
                                       Immunomodulatory            0.66                                                  0.36--1.20                                                   0.1708
                                       Mesenchymal                 0.82                                                  0.5--1.33                                                    0.4204
                                       Mesenchymal stem-like       0.40                                                  0.14--1.16                                                   0.0794
                                       Luminal androgen receptor   0.64^[a](#tfn11-ol-0-0-10722){ref-type="table-fn"}^   0.41--1.00^[a](#tfn11-ol-0-0-10722){ref-type="table-fn"}^    0.0471^[a](#tfn11-ol-0-0-10722){ref-type="table-fn"}^
  MAGEB6               1552858_at      Basal-like 1                0.64                                                  0.31--1.33                                                   0.2293
                                       Basal-like 2                0.43^[a](#tfn11-ol-0-0-10722){ref-type="table-fn"}^   0.19--0.97^[a](#tfn11-ol-0-0-10722){ref-type="table-fn"}^    0.0356^[a](#tfn11-ol-0-0-10722){ref-type="table-fn"}^
                                       Immunomodulatory            0.41^[a](#tfn11-ol-0-0-10722){ref-type="table-fn"}^   0.17--0.96^[a](#tfn11-ol-0-0-10722){ref-type="table-fn"}^    0.0333^[a](#tfn11-ol-0-0-10722){ref-type="table-fn"}^
                                       Mesenchymal                 0.47^[a](#tfn11-ol-0-0-10722){ref-type="table-fn"}^   0.24--0.89^[a](#tfn11-ol-0-0-10722){ref-type="table-fn"}^    0.0181^[a](#tfn11-ol-0-0-10722){ref-type="table-fn"}^
                                       Mesenchymal stem-like       0.54                                                  0.17--1.72                                                   0.2907
                                       Luminal androgen receptor   0.58                                                  0.33--1.02                                                   0.0546
  MAGEB18              1552913_at      Basal-like 1                1.75                                                  0.90--3.40                                                   0.0922
                                       Basal-like 2                0.51                                                  0.22--1.18                                                   0.1092
                                       Immunomodulatory            2.39^[b](#tfn12-ol-0-0-10722){ref-type="table-fn"}^   1.03--5.51^[b](#tfn12-ol-0-0-10722){ref-type="table-fn"}^    0.0353^[b](#tfn12-ol-0-0-10722){ref-type="table-fn"}^
                                       Mesenchymal                 1.70                                                  0.98--2.93                                                   0.0543
                                       Mesenchymal stem-like       0.19^[a](#tfn11-ol-0-0-10722){ref-type="table-fn"}^   0.05--0.66^[a](#tfn11-ol-0-0-10722){ref-type="table-fn"}^    0.0039^[a](#tfn11-ol-0-0-10722){ref-type="table-fn"}^
                                       Luminal androgen receptor   2.04^[b](#tfn12-ol-0-0-10722){ref-type="table-fn"}^   1.11--3.77^[b](#tfn12-ol-0-0-10722){ref-type="table-fn"}^    0.0211^[b](#tfn12-ol-0-0-10722){ref-type="table-fn"}^
  MAGEC3               216592_at       Basal-like 1                0.63                                                  0.35--1.14                                                   0.1255
                                       Basal-like 2                0.55                                                  0.27--1.12                                                   0.0933
                                       Immunomodulatory            0.69                                                  0.35--1.37                                                   0.2890
                                       Mesenchymal                 0.65                                                  0.43--1.00                                                   0.0505
                                       Mesenchymal stem-like       0.32^[a](#tfn11-ol-0-0-10722){ref-type="table-fn"}^   0.12--0.85^[a](#tfn11-ol-0-0-10722){ref-type="table-fn"}^    0.0159^[a](#tfn11-ol-0-0-10722){ref-type="table-fn"}^
                                       Luminal androgen receptor   0.73                                                  0.47--1.12                                                   0.1508
  MAGED2               213627_at       Basal-like 1                1.68^[b](#tfn12-ol-0-0-10722){ref-type="table-fn"}^   1.02--2.77^[b](#tfn12-ol-0-0-10722){ref-type="table-fn"}^    0.0386^[b](#tfn12-ol-0-0-10722){ref-type="table-fn"}^
                                       Basal-like 2                0.46^[a](#tfn11-ol-0-0-10722){ref-type="table-fn"}^   0.23--0.95^[a](#tfn11-ol-0-0-10722){ref-type="table-fn"}^    0.0308^[a](#tfn11-ol-0-0-10722){ref-type="table-fn"}^
                                       Immunomodulatory            1.34                                                  0.72--2.49                                                   0.3553
                                       Mesenchymal                 1.43                                                  0.83--2.46                                                   0.1993
                                       Mesenchymal stem-like       0.60                                                  0.27--1.32                                                   0.2002
                                       Luminal androgen receptor   1.32                                                  0.86--2.02                                                   0.2000
  MAGED3               205028_at       Basal-like 1                0.74                                                  0.43--1.25                                                   0.2584
                                       Basal-like 2                2.93^[b](#tfn12-ol-0-0-10722){ref-type="table-fn"}^   1.34--6.39^[b](#tfn12-ol-0-0-10722){ref-type="table-fn"}^    0.0047^[b](#tfn12-ol-0-0-10722){ref-type="table-fn"}^
                                       Immunomodulatory            1.46                                                  0.80--2.65                                                   0.2138
                                       Mesenchymal                 1.59^[b](#tfn12-ol-0-0-10722){ref-type="table-fn"}^   1.04--2.43^[b](#tfn12-ol-0-0-10722){ref-type="table-fn"}^    0.0317^[b](#tfn12-ol-0-0-10722){ref-type="table-fn"}^
                                       Mesenchymal stem-like       2.06                                                  0.92--4.63                                                   0.0729
                                       Luminal androgen receptor   0.70                                                  0.47--1.05                                                   0.0839
  MAGED4               221261_x\_at    Basal-like 1                1.61^[b](#tfn12-ol-0-0-10722){ref-type="table-fn"}^   1.00--2.59^[b](#tfn12-ol-0-0-10722){ref-type="table-fn"}^    0.0494^[b](#tfn12-ol-0-0-10722){ref-type="table-fn"}^
                                       Basal-like 2                0.56                                                  0.25--1.26                                                   0.1558
                                       Immunomodulatory            0.64                                                  0.34--1.18                                                   0.1502
                                       Mesenchymal                 0.80                                                  0.51--1.26                                                   0.3402
                                       Mesenchymal stem-like       3.16^[b](#tfn12-ol-0-0-10722){ref-type="table-fn"}^   0.94--10.56^[b](#tfn12-ol-0-0-10722){ref-type="table-fn"}^   0.0488^[b](#tfn12-ol-0-0-10722){ref-type="table-fn"}^
                                       Luminal androgen receptor   1.59^[b](#tfn12-ol-0-0-10722){ref-type="table-fn"}^   1.05--2.40^[b](#tfn12-ol-0-0-10722){ref-type="table-fn"}^    0.0267^[b](#tfn12-ol-0-0-10722){ref-type="table-fn"}^
  MAGEE1               1556047_s\_at   Basal-like 1                1.74                                                  0.90--3.37                                                   0.0980
                                       Basal-like 2                0.25^[a](#tfn11-ol-0-0-10722){ref-type="table-fn"}^   0.07--0.85^[a](#tfn11-ol-0-0-10722){ref-type="table-fn"}^    0.0160^[a](#tfn11-ol-0-0-10722){ref-type="table-fn"}^
                                       Immunomodulatory            0.41                                                  0.12--1.37                                                   0.1343
                                       Mesenchymal                 1.82^[b](#tfn12-ol-0-0-10722){ref-type="table-fn"}^   1.06--3.15^[b](#tfn12-ol-0-0-10722){ref-type="table-fn"}^    0.0284^[b](#tfn12-ol-0-0-10722){ref-type="table-fn"}^
                                       Mesenchymal stem-like       0.41                                                  0.15--1.13                                                   0.0757
                                       Luminal androgen receptor   0.73                                                  0.43--1.26                                                   0.2576
  MAGEE2               1553254_at      Basal-like 1                0.58                                                  0.27--1.26                                                   0.1636
                                       Basal-like 2                0.60                                                  0.25--1.43                                                   0.2440
                                       Immunomodulatory            1.91                                                  0.82--4.41                                                   0.1257
                                       Mesenchymal                 0.72                                                  0.39--1.30                                                   0.2718
                                       Mesenchymal stem-like       0.34^[a](#tfn11-ol-0-0-10722){ref-type="table-fn"}^   0.12--0.97^[a](#tfn11-ol-0-0-10722){ref-type="table-fn"}^    0.0345^[a](#tfn11-ol-0-0-10722){ref-type="table-fn"}^
                                       Luminal androgen receptor   1.59                                                  0.90--2.80                                                   0.1067
  MAGEF1               218176_at       Basal-like 1                0.75                                                  0.46--1.23                                                   0.2538
                                       Basal-like 2                0.33^[a](#tfn11-ol-0-0-10722){ref-type="table-fn"}^   0.14--0.81^[a](#tfn11-ol-0-0-10722){ref-type="table-fn"}^    0.0110^[a](#tfn11-ol-0-0-10722){ref-type="table-fn"}^
                                       Immunomodulatory            0.57                                                  0.32--1.04                                                   0.0623
                                       Mesenchymal                 1.67                                                  0.98--2.84                                                   0.0573
                                       Mesenchymal stem-like       0.41^[a](#tfn11-ol-0-0-10722){ref-type="table-fn"}^   0.18--0.94^[a](#tfn11-ol-0-0-10722){ref-type="table-fn"}^    0.0292^[a](#tfn11-ol-0-0-10722){ref-type="table-fn"}^
                                       Luminal androgen receptor   0.61^[a](#tfn11-ol-0-0-10722){ref-type="table-fn"}^   0.41--0.91^[a](#tfn11-ol-0-0-10722){ref-type="table-fn"}^    0.0158^[a](#tfn11-ol-0-0-10722){ref-type="table-fn"}^
  MAGEH1               218573_at       Basal-like 1                1.87^[b](#tfn12-ol-0-0-10722){ref-type="table-fn"}^   1.16--3.02^[b](#tfn12-ol-0-0-10722){ref-type="table-fn"}^    0.0090^[b](#tfn12-ol-0-0-10722){ref-type="table-fn"}^
                                       Basal-like 2                2.17^[b](#tfn12-ol-0-0-10722){ref-type="table-fn"}^   1.06--4.40^[b](#tfn12-ol-0-0-10722){ref-type="table-fn"}^    0.0288^[b](#tfn12-ol-0-0-10722){ref-type="table-fn"}^
                                       Immunomodulatory            1.89^[b](#tfn12-ol-0-0-10722){ref-type="table-fn"}^   1.05--3.42^[b](#tfn12-ol-0-0-10722){ref-type="table-fn"}^    0.0314^[b](#tfn12-ol-0-0-10722){ref-type="table-fn"}^
                                       Mesenchymal                 1.56^[b](#tfn12-ol-0-0-10722){ref-type="table-fn"}^   1.01--2.42^[b](#tfn12-ol-0-0-10722){ref-type="table-fn"}^    0.0421^[b](#tfn12-ol-0-0-10722){ref-type="table-fn"}^
                                       Mesenchymal stem-like       0.56                                                  0.23--1.36                                                   0.1943
                                       Luminal androgen receptor   1.72^[b](#tfn12-ol-0-0-10722){ref-type="table-fn"}^   1.15--2.59^[b](#tfn12-ol-0-0-10722){ref-type="table-fn"}^    0.0079^[b](#tfn12-ol-0-0-10722){ref-type="table-fn"}^
  MAGEL2               219894_at       Basal-like 1                1.55                                                  0.96--2.49                                                   0.0726
                                       Basal-like 2                0.55                                                  0.25--1.20                                                   0.1258
                                       Immunomodulatory            1.63                                                  0.82--3.25                                                   0.1574
                                       Mesenchymal                 0.62^[a](#tfn11-ol-0-0-10722){ref-type="table-fn"}^   0.39--0.99^[a](#tfn11-ol-0-0-10722){ref-type="table-fn"}^    0.0433^[a](#tfn11-ol-0-0-10722){ref-type="table-fn"}^
                                       Mesenchymal stem-like       1.50                                                  0.67--3.33                                                   0.3206
                                       Luminal androgen receptor   0.61^[a](#tfn11-ol-0-0-10722){ref-type="table-fn"}^   0.41--0.93^[a](#tfn11-ol-0-0-10722){ref-type="table-fn"}^    0.0188^[a](#tfn11-ol-0-0-10722){ref-type="table-fn"}^

P\<0.05 was considered to indicate a statistically significant difference.

High mRNA expression levels associated with improved RFS

high mRNA expression levels associated with worse RFS. Total patients assigned a Pietenpol subtype ([@b31-ol-0-0-10722]), n=1,246; patients with the basal-like 1 subtype, n=239; patients with the basal-like 2 subtype, n=97; patients with the immunomodulatory subtype, n=290; patients with the mesenchymal subtype, n=229; patients with the mesenchymal stem-like subtype, n=115; patients with the luminal androgen receptor subtype, n=276. CI, confidence interval; HR, hazard ratio; MAGE, melanoma-associated antigen.
